Steve Self is to stand down as development director at e-Therapeutics PLC (LON:ETX) and leave the company at the end of the month.
The drugs discovery and developer noted in its stock market statement that it had indicated back in March, at the time of its full-year results, that it intended to focus more on the discovery side of things, and the implication is that this has been the reason behind the parting of the ways with Self.
"Steve joined e-Therapeutics in December 2010 following a distinguished career at The Wellcome Foundation, Boots Healthcare and as R&D Director of Merck's Generic Global business. We thank him for his significant contribution to our activities and wish him continuing success in his new endeavours," said Iain Ross, executive chairman of e-Therapeutics.
The company is clearly going through a transitional phase as the two most advanced of its discovery compounds approach the lead candidate selection process, ahead of entering pre-clinical development in the coming months.
Professor Malcolm Young, who founded the company, stood down as chief executive in July, with chairman Ross assuming executive duties until a replacement can be found.